Phase II Trial Assessing Safety, Efficacy and Immune Correlates of Heterologous Prime-Boost with pBI-11 (IM) and TA-HPV (IM) Plus Pembrolizumab for Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer
M. Gibson, P. Savvides, F. Worden, R. Gopalakrishnan, T. Wu, R. Roden, E. Heimann-Nichols, Y.N. Chang
{"title":"Phase II Trial Assessing Safety, Efficacy and Immune Correlates of Heterologous Prime-Boost with pBI-11 (IM) and TA-HPV (IM) Plus Pembrolizumab for Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer","authors":"M. Gibson, P. Savvides, F. Worden, R. Gopalakrishnan, T. Wu, R. Roden, E. Heimann-Nichols, Y.N. Chang","doi":"10.1016/j.ijrobp.2024.01.197","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":14219,"journal":{"name":"International Journal of Radiation Oncology*Biology*Physics","volume":"83 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology*Biology*Physics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.01.197","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
